Defining stakeholders’ research priorities in progressive pulmonary fibrosis in the United Kingdom
L. Fabbri (ret Turner Warwick Centre for Fibrosing Lung Disease, National Heart and Lung Institute, Imperial College London, Division of Respiratory Medicine, University of Nottingham, Nottingham Biomedical Research Centre, National Institute for Health ResearchLondon, United Kingdom), L. Wright (Peterborough, United Kingdom), S. Jones (Peterborough, United Kingdom), W. Adams (Peterborough, United Kingdom), K. Cowan (Southampton, United Kingdom), S. Hart (York, United Kingdom), A. Russell (Exeter, United Kingdom), M. Gibbons (Exeter, United Kingdom), N. Chaudhuri (Belfast, United Kingdom), J. Lynch-Wilson (Carmarthen, United Kingdom), G. Jenkins (London, United Kingdom)
Source: International Congress 2022 – How to prevent progression in idiopathic interstitial pneumonias
 
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
L. Fabbri (ret Turner Warwick Centre for Fibrosing Lung Disease, National Heart and Lung Institute, Imperial College London, Division of Respiratory Medicine, University of Nottingham, Nottingham Biomedical Research Centre, National Institute for Health ResearchLondon, United Kingdom), L. Wright (Peterborough, United Kingdom), S. Jones (Peterborough, United Kingdom), W. Adams (Peterborough, United Kingdom), K. Cowan (Southampton, United Kingdom), S. Hart (York, United Kingdom), A. Russell (Exeter, United Kingdom), M. Gibbons (Exeter, United Kingdom), N. Chaudhuri (Belfast, United Kingdom), J. Lynch-Wilson (Carmarthen, United Kingdom), G. Jenkins (London, United Kingdom). Defining stakeholders’ research priorities in progressive pulmonary fibrosis in the United Kingdom. 2654
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|